Related Experiment Video
Updated: Jun 18, 2026
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
Immunotherapy for Pediatric Gliomas: CAR-T Cells Against B7H3: A Review of the Literature
Yolanda Santiago-Vicente1,2, Manuel de Jesús Castillejos-López3, Liliana Carmona-Aparicio4
1Iztacala Faculty of Higher Studies, Tlalnepantla, México.
Background:
B7H3 is a co-stimulatory molecule for immune reactions found on the surface of tumor cells in a wide variety of tumors. Preclinical and clinical studies have reported it as a tumor target towards which various immunotherapy modalities could be directed. So far, good results have been obtained in hematological neoplasms; however, a contrasting situation is evident in solid tumors, including those of the CNS, which show high refractoriness to current treatments. The appearance of cellular immunotherapies has transformed oncology due to the reinforcement of the immune response that is compromised in people with cancer.
Objective:
This article aims to review the literature to describe the advancement in knowledge on B7H3 as a target of CAR-T cells in pediatric gliomas to consider them as an alternative in the treatment of these patients.
Results:
Although B7H3 is considered a suitable candidate as a target agent for various immunotherapy techniques, there are still limitations in using CAR-T cells to achieve the desired success.
Conclusion:
Results obtained with CAR-T cells can be further improved by the suggested proposals; therefore, more clinical trials are needed to study this new therapy in children with gliomas.
Insights
CAR-T cell therapy targeting B7H3 shows promise for pediatric gliomas, offering a new avenue for treatment. Further clinical trials are essential to optimize this immunotherapy approach for improved outcomes in children.
Area of Science:
- Oncology
- Immunology
- Cellular Therapy
Background:
- B7H3 is a tumor-associated co-stimulatory molecule implicated in various cancers.
- While effective in hematological neoplasms, solid tumors like CNS gliomas exhibit treatment resistance.
- Cellular immunotherapies, including CAR-T cells, enhance anti-tumor immune responses.
Approach:
- This review synthesizes current literature on B7H3 as a target for CAR-T cell therapy.
- Focuses on the application of B7H3-targeted CAR-T cells in pediatric gliomas.
- Evaluates the potential of this approach as an alternative treatment strategy.
Key Points:
- B7H3 is a promising target for immunotherapy across diverse tumor types.
- CAR-T cell therapy has shown efficacy in hematological cancers but faces challenges in solid tumors.
- Pediatric gliomas are refractory to current treatments, necessitating novel therapeutic strategies.
Conclusions:
- B7H3-targeted CAR-T cells represent a potential therapeutic option for pediatric gliomas.
- Current limitations in CAR-T cell therapy require further research and development.
- Additional clinical trials are crucial to validate and refine B7H3-targeted CAR-T cell efficacy in children with gliomas.
More Related Videos
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
05:22Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor CAR T Cell Infusions in Mice
Published on: February 24, 2023
